RxSight had its price objective decreased by equities research analysts at Stifel Nicolaus from $40.00 to $35.00 in a report released on Monday,Benzinga reports. The brokerage currently has a "hold" rating on the stock. Stifel Nicolaus' target price points to a potential upside of 22.98% from the stock's previous close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.